T ranscatheter aortic valve replacement (TAVR) has revolutionized management of elderly patients with severe aortic stenosis, 1,2 but post-TAVR neurological events remain a concern for patients and physicians. Although occurrence of post-TAVR stroke has fallen from ≈5% in initial trials to 3% in recent reports, reducing this risk is essential for advancing this technology into lower-risk patient cohorts. 3
variability in their diagnosis, and use of different analytical methods make it difficult to reach firm conclusions. [6] [7] [8] The PARTNER trial (Placement of Aortic Transcatheter Valves) provides a well-characterized patient population undergoing TAVR using a balloon-expandable device, for which the incidence, timing, risk factors, and outcomes of neurological events occurring ≤5 years have been described. 7, [9] [10] [11] [12] Our previous publication examining incidence, risk factors, and outcomes of neurological events in the high-risk randomized cohort of the PARTNER trial was based on early followup and few events, which necessitated combining stroke and transient ischemic attack (TIA) as a composite. 7 In the present study, all TAVR patients from all PARTNER cohorts have been included, follow-up has been extended, and the number of events has permitted in-depth insight into timing, risk factors, and outcomes of neurological events after TAVR, with stroke and TIA analyzed separately.
Methods Patients
From April 2007 to February 2012, 2621 high-risk or inoperable patients with severe aortic stenosis were enrolled in PARTNER. Based on a patient's arterial anatomy, delivery was allocated in a transfemoral (TF) first strategy, with transapical (TA) access reserved for those with iliofemoral impediments to valve delivery and insertion. A total of 1521 patients underwent TF-TAVR and 1100 TA-TAVR using 22or 24-French sheaths to insert 23 mm or 26 mm SAPIEN prosthetic aortic valves (Edwards Lifesciences, Irvine, CA). This as-treated study included all PARTNER trial cohorts: 62 roll-in patients (19 TA and 43 TF), 344 randomized cohort A (high risk) patients (104 TA and 240 TF), 175 randomized cohort B (inoperable) TF patients, 40 randomized continuing access TF patients, and 2000 nonrandomized continuing access patients (977 TA and 1023 TF). PARTNER trial selection criteria and design, along with technical details of the TAVR procedure, have been previously reported. 11, 12 Patients who underwent TA-TAVR had more comorbidities than those who underwent TF-TAVR, including cerebrovascular disease (prior stroke, TIA, dementia, carotid disease) in 43% versus 32% and a carotid procedure in 16% versus 7.6%, but had similar prevalence of pre-TAVR stroke and dementia (Table 1 ). Peripheral arterial disease was more common in TA-TAVR patients (98%) than in TF-TAVR patients (49%) and more had prior coronary interventions. Procedure time, fluoroscopy time, and volume of contrast media were greater in TF-TAVR than in TA-TAVR patients ( Table 2 ).
End Points
The primary end points of the study were stroke or TIA occurring during or after TAVR. Stroke was defined as a focal neurological deficit lasting 24 hours or longer or a focal neurological deficit lasting <24 hours with imaging findings of acute cerebral infarction or hemorrhage. Stroke was further classified as ischemic, hemorrhagic (epidural, subdural, and subarachnoid), or ischemic with hemorrhagic conversion. TIA was defined as a focal neurological deficit fully reversible within 24 hours in the absence of any new imaging findings of infarction or other primary medical cause (eg, hypoglycemia or hypoxia). In-hospital neurological events were identified by clinicians caring for patients after TAVR. At each follow-up visit, patients were assessed according to the National Institutes of Health stroke scale, and any increase from baseline was reported as a potential adverse event. The independent Clinical Events Committee, which included a neurologist, reviewed imaging studies, neurology consults, operative and discharge reports, laboratory reports, and all notes for type and duration of symptoms.
Secondary end points were the competing risk of death before these neurological events, death after them, and their mortality cost.
Because TA-TAVR was not performed initially during the PARTNER trial, follow-up is described separately for each group. For TF-TAVR, median follow-up was 1 year (mean±SD 1.6±1.1 years). A total of 2389 patient-years of data were available for analyses; 25% of survivors were followed >2 years and 10% >3 years. For TA-TAVR, median follow-up was 1 year (mean±SD 1.2±0.84 years). A total of 1282 patient years of data were available for analyses; 25% of survivors were followed >2 years and 10% >2.5 years.
Data Analysis
Data analysis was based on the as treated TAVR population. Data used were from a December 2012 locked data set provided to the PARTNER Publications Office by Edwards Lifesciences. Data analysis was performed by PARTNER Publications Office investigators, with no sponsor involvement in substudy proposal, design, analysis, interpretation, or decision to publish. The Institutional Review Board at each participating site approved the trial, and all patients provided written informed consent. Data were analyzed using SAS statistical software (SAS v9.2; SAS Inc, Cary) and R software version 2.15.3.
Time-Related Events
Time-related events were estimated nonparametrically by the Kaplan-Meier method and parametrically by a multiphase nonproportional hazards model, 13 by which a smooth representation of instantaneous risk (hazard function) was estimated across time. Estimates were made for stroke and TIA, both overall and for TF-and TA-TAVR groups. Although a neurological event can occur more than once, this happened only 6 times, so all analyses were performed using the first event rather than repeating events.
We placed stroke and TIA into the context of the ongoing competing risk of death before these neurological events. 14 Finally, we assessed mortality following a neurological event.
WHAT IS KNOWN
• Stroke after transcatheter aortic valve replacement (TAVR) is an important clinical problem; however, the reported stroke rate in current era is lower than that in the past, especially in lower-risk patients, and with use of newer devices.
• Stroke rate after TAVR is not higher compared with surgical aortic valve replacement; in fact, recent studies suggest that it may be lower than surgical aortic valve replacement.
• Stroke after TAVR results in significantly higher morbidity and mortality.
WHAT THE STUDY ADDS
• Risk of stroke or transient ischemic attack is highest early after TAVR. Importantly, risk of strokes after the initial periprocedural period is not high. This finding provides rationale for the use of emboli prevention strategies at time of procedure.
• Transient ischemic attack after TAVR also increases risk of mortality, highlighting adverse implications of any periprocedural emboli to the brain.
• More balloon post dilatation and lack of dual antiplatelet therapy before procedure were associated with higher risk of early stroke. Strategies to minimize these may help to reduce the risk of stroke. Stroke and TIA After TAVR
Risk Factors for Neurological Events
Incremental risk factors for stroke were identified simultaneously within each hazard phase, with a 2-sided P value criterion for retention of variables in the model of 0.05, using the 56 variables shown in Appendix E1 in the Data Supplement. Initial variable selection used bagging (bootstrap aggregation), 15, 16 a method suited to screening a large number of variables compared with number of events that avoids both the prematurity of a priori variable selection in this TAVR trial and the possibility of Type II error by analyzing only univariable statistically significant variables. This unsupervised machine-learning method reduces the majority of variables to the level of noise and reveals variables contributing to signal by averaging over the results of a multitude of individual analyses of bootstrap samples. Thus, for this analysis and others mentioned subsequently, patients were randomly selected from the original data set to form 1000 bootstrap data sets of equal size. Risk factors were identified for each of these data sets using automated forward stepwise selection. Occurrence of variables selected in these models was tabulated (the aggregation step), and those appearing in at least 50% of models were retained in the final analysis (Appendix E1 in the Data Supplement). This median rule tends to balance Type I and Type II error. Results were verified using Random Forests for Survival, a nonparametric machine-learning method that permitted graphical display of relationships of continuous variables to survival (partial dependency plots), adjusted for 56 variables without model assumptions. 17, 18 We then performed several focused investigations of additional variables identified as risk factors in other studies.
Competing Risks of Death and Neurological Events
Actuarial and parametric estimates of stroke or TIA describe the isolated probability of experiencing these events. However, as time passes, patients die, and the method of competing risks was used to estimate the likelihood that patients would still be alive and free of a neurological event. For this, a common interval was defined as the earliest of either death or neurological event. Patients were then transitioned from being alive without a neurological event into 2 mutually exclusive states: neurological event or death before such an event. Freedom from each event was estimated by the nonparametric product-limit method, with variances based on the Greenwood formula. Because of the difference in neurological event risk according to TF or TA stratum, the TAVR group was analyzed according to as-stratified access, recognizing that access is indicative of more generalized atherosclerotic burden.
Survival after a Neurological Event
Survival after stroke or TIA was estimated nonparametrically and parametrically, with time zero as time of the first event. Mere depiction of survival after a neurological event does not address mortality cost. For this, we need to estimate survival had the event not occurred. Thus, we first estimated survival before a neurological event for all patients from the time of the procedure. Next, we used the parametric equation for survival before a neurological event to generate a survival curve for each patient who experienced a neurological event after the time the event occurred. This is known as conditional survival, which starts at 100% at the time of a neurological event. We then computed the average of all curves, which is the expected survival beyond the time of the neurological event had it never occurred. We then compared the actual survival curve from the time of neurological event to the expected survival curve had the event not occurred.
Missing Values
During unsupervised bagging for variable selection, we used simple means imputation for missing values. However, to develop final models, we used multiple imputation based on all 56 covariables (not the outcome). Of the 12 variables in the final models, 2 had no missing data, 5 had 4% missing data, 4 had 1% to 3% missing data, and 1 had 6.4% missing data. The pattern of missing data appeared arbitrarily, so we assumed missing at random. Therefore, we performed 5-fold multiple imputation using a Markov chain Monte Carlo technique (SAS PROC MI) 19 to yield final regression coefficient estimates, the variance-covariance matrix, and P values (SAS PROC MIANALYZE).
Presentation
Continuous variables are summarized as mean±standard deviation or as equivalent 25th, 50th (median) and 75th percentiles when distribution of values is skewed. Categorical variables are summarized by frequencies and percentages. Both nonparametric (actuarial) and parametric estimates of time-to-event occurrence are presented with asymmetrical 95% confidence intervals.
Results

Time-Related Stroke
A total of 134 first strokes (87 in TF and 47 in TA) occurred during the follow-up period, mostly during or early after TAVR ( Table I in for TF and 2.7%, 4.1%, and 7% for TA, respectively. After adjusting for the competing risk of death before stroke, likelihood of stroke was 3.7%, 5.1%, and 6.1% for TF and 2.6%, 3.9%, and 5.2% for TA, respectively ( Figure 1B; Figure IIA and IIB in the Data Supplement). Early and late stroke risks were higher for patients with a CHA 2 DS 2 VASc score >3 compared with those with a score of ≤3 (Table II in the Data Supplement; Figure 2 ), although only 4.5% of patients had a CHA 2 DS 2 VASc score of ≤3.
Risk Factors for Stroke After TF-TAVR
Higher pre-TAVR aortic valve peak gradient was associated with early strokes (primarily those occurring within ≈7 days of TAVR; Table 3 ; Figure 
Risk Factors for Stroke After TA-TAVR
Incremental risk factors for early stroke were pure aortic stenosis without regurgitation ( Figure VIII 
Survival After Stroke
Patients who experienced a stroke had lower 1-year survival than patients who did not (TF, 47% after stroke versus 82%; TA, 53% after stroke versus 80%; Figure 3A and 3B). 
Time-Related TIA
Survival After TIA
Patients who experienced a TIA had lower 1-year estimated survival than patients who did not (TF, 64% after TIA versus 83%; TA, 64% after TIA versus 83%; Figure 4A and 4B).
Discussion
Principal Findings
This study demonstrates that risk of stroke and TIA was highest in the first week after TAVR, highlighting the importance of procedural modifications to curtail this risk. Without adjusting for baseline characteristics, risk was less after TA-than after TF-TAVR. Risk factors also differed between these groups, with possibly more effect of a learning curve in TA and of procedure time in TF. TIA posed a significant mortality risk, albeit smaller than stroke.
Findings in Context
Our previous publication of neurological events in the randomized high-risk cohort A of PARTNER focused on a comparison of TAVR with surgical aortic valve replacement. 7 Only 31 events (23 strokes and 8 TIAs) occurred among TAVR patients, limiting multivariable analysis. In the present study, not only were there sufficient events to study stroke and TIA separately, but we were able to separately identify risk factors according to access-TA or TF. Increased severity of aortic stenosis and history of cerebrovascular disease were early risk factors identified previously in cohort A (all cases) and in this study only after TF-TAVR. The timing of stroke after TAVR is an important factor when considering periprocedural modifications that may mitigate risk. Strokes within the first 7 days may be considered procedural because recognition of stroke may not be immediate and symptom onset may be delayed until the thrombus forms on the embolized particles. Early risk of stroke occurred after both TF-and TA-TAVR, suggesting that emboli-prevention devices and appropriate pharmacotherapy may substantially reduce this risk. An emboli-protection device have been evaluated in single center randomized clinical trial (CLEAN-TAVI [Claret Embolic Protection and TAVI Trial]) and 2 multicenter randomized trials are ongoing (SENTINEL [Cerebral Protection in Transcatheter Aortic Valve Replacement; clinicaltrials.gov/ct2/show/NCT02214277] and REFLECT [Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation; clinicaltrials. gov/ct2/show/NCT02536196]). 20, 21 In addition, nonendothelialized valve stent struts or stagnant eddy flow in the niches behind the native calcified cusps may present a thrombogenic surface, thus, increasing the risk of delayed stroke. 22 Access-related differences in stroke risk are still debated. In PARTNER, unadjusted stroke risk was higher after TA-than after TF-TAVR; however, after adjusting for baseline characteristics, risk was similar. 23 Other studies and meta-analyses have shown no difference in stroke risk based on access site. 24 Risk of stroke after TAVR has decreased over time, though less pronounced in the TF group, 3, 25 where evolution of the delivery system and refined patient selection may have contributed to a decrease. Late hazard for stroke appeared to be slightly higher after TA-TAVR, potentially pointing to the higher vascular risk in this population and highlighting the need for better long-term pharmacotherapy.
Risk factors for stroke differ between TA-and TF-TAVR groups. In the TA-TAVR group, possibly more pacing runs and reliably more postdilatations were associated with higher risk of stroke, suggesting that procedural modification may be important in reducing these events. Recently, operators have minimized pacing runs by avoiding balloon dilatation before valve implantation and reduced postdilatation through proper valve sizing. Higher stroke risk in patients with pure aortic stenosis without regurgitation could be because of more severe aortic stenosis, as seen in the TF-TAVR group and documented in the previous study. 7 Although we did not have quantification of valve calcification, we interpret the risk factor, higher pre-TAVR aortic valve peak gradient, as a surrogate for more severe aortic stenosis.
Clinical Implications
Most TAVR patients are not on antiplatelet therapy because of increased risk of bleeding. In the current literature, there is controversy regarding the safest and most effective antithrombotic or antiplatelet regimen in the periprocedural period. Several studies have indicated that dual antiplatelet therapy may simply increase risk of major bleeding without affecting the occurrence of cerebrovascular events. 5, [26] [27] [28] Further studies are needed to determine whether periprocedural dual antiplatelet therapy can reduce the risk of stroke without increasing risk of bleeding.
Postprocedural warfarin could also be beneficial for these patients. According to the latest American College of Cardiology/American Heart Association valvular heart disease guidelines, 29 anticoagulation with warfarin is considered reasonable within the first 3 months after bioprosthetic AVR (Class IIb recommendation). This recommendation is based on the results of the Danish National Patient Registry, which demonstrated (albeit controversially) that discontinuation of warfarin within the first 6 months after AVR was associated with increased risk of cardiovascular death. 30 Whether warfarin will reduce cerebrovascular events after TAVR awaits further clinical studies.
Improvements in the TAVR procedure may decrease risk of post-TAVR stroke. We observed that longer procedure time and more pacing runs and postdilatations were associated with a higher risk of stroke after TAVR (with variable reliability). Advances in valve and delivery-system design, along with increasing experience, may reduce procedure times and, thereby, reduce occurrence of stroke.
Long-term stroke risk is associated with thromboembolism from atrial fibrillation, thrombus formation around the native calcified cusps, or aortic arch manipulation. A higher CHA 2 DS 2 VASc score may be associated with long-term stroke, though it was not an independent risk factor and may have less discriminating power in elderly patients with multiple comorbidities. 29 TIA was associated with a smaller but significant risk of mortality. This is the first time that such an association has been described in a prospective TAVR trial.
Limitations
Periprocedural neurological assessment was not routinely performed; therefore, occurrence of neurological events may have been underestimated. 30 Clinical Events Committee adjudication of events could be limited because of lack of information; however, this data set contains a large number of well-characterized patients from multiple institutions. With the advent of transaortic TAVR and smaller TAVR delivery systems, TA-TAVR has become less common.
Conclusions
Risk of stroke or TIA was highest early after TAVR, though this risk decreased over the study period. These events are associated with increased risk of 1-year mortality, highlighting the need for antiplatelet therapy and emboli-prevention devices, along with procedural modifications, that may mitigate this risk.
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